Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus

• Main Authors: Mohammed Salah Eldin Abdelbaky (Author), Tarek Ahmad El Mamoun (Author), Fatma Ibrahim Mabrouk (Author), Rasha Mohamad Hassan (Author)
• Formato: Libro
• Publicado: SpringerOpen, 2021-06-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Abstract Background Hydroxychloroquine (HCQ) is an antimalarial drug, recently used in COVID-19 treatment. Also it is considered over many years the cornerstone in treating systemic lupus erythematosus (SLE) in adults and children. The incidence of retinal affection and retinal toxicity from hydroxy...